A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS2 score in Japan

Takehiro Kimura, Ataru Igarashi, Shunya Ikeda, Kazuaki Nakajima, Shin Kashimura, Akira Kunitomi, Yoshinori Katsumata, Takahiko Nishiyama, Nobuhiro Nishiyama, Kotaro Fukumoto, Yoko Tanimoto, Yoshiyasu Aizawa, Keiichi Fukuda, Seiji Takatsuki

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: We aimed to clarify the cost-effectiveness of an expensive combination therapy for atrial fibrillation (AF) using both catheter ablation and dabigatran compared with warfarin at each CHADS2 score for patients in Japan. Methods: A Markov model was constructed to analyze costs and quality-adjusted life years associated with AF therapeutic options with a time horizon of 10 years. The target population was 60-year-old patients with paroxysmal AF. The indication for anticoagulation was determined according to the Japanese guideline. Anticoagulation-related data were derived from the RE-LY study and the AF recurrence rate was set at 2.7% per month during the first 12 months and at 0.40% per month afterwards. Stroke risk was determined according to AF recurrence, anticoagulation, and CHADS2 score. The risks for stroke recurrence and stroke death were also considered. Costs were calculated from the healthcare payer's perspective, and only direct medical costs were included. Results: Warfarin was the most preferred option for patients with a CHADS2 score of 0 from a health economics aspect. Ablation under warfarin was preferred for a CHADS2 score of 1-3, while ablation under dabigatran was preferred for a CHADS2 score ≥4. The quality of life score for AF had the largest impact on the incremental cost-effectiveness ratios in the analysis between the anticoagulation arm and the anticoagulation+ablation arm for a CHADS2 score of 2. Within the range of the Japanese willingness-to-pay threshold (¥5,000,000), the ablation+warfarin arm became the best option with its probability of 81.7% for a CHADS2 score of 2; the dabigatran+ablation arm was the most preferred option with its probability of 56.1% for a CHADS2 score of 4. Conclusions: Ablation under dabigatran therapy is an expensive therapeutic option, but it might benefit patients with a low quality of life and a high CHADS2 score.

Original languageEnglish
JournalJournal of Cardiology
DOIs
Publication statusAccepted/In press - 2015 Jun 30

Fingerprint

Catheter Ablation
Warfarin
Atrial Fibrillation
Cost-Benefit Analysis
Japan
Stroke
Costs and Cost Analysis
Recurrence
Quality of Life
Quality-Adjusted Life Years
Health Services Needs and Demand
Therapeutics
Dabigatran
Economics
Guidelines
Delivery of Health Care
Health

Keywords

  • Atrial fibrillation
  • Catheter ablation
  • Cost-utility analysis
  • Dabigatran
  • Warfarin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS2 score in Japan. / Kimura, Takehiro; Igarashi, Ataru; Ikeda, Shunya; Nakajima, Kazuaki; Kashimura, Shin; Kunitomi, Akira; Katsumata, Yoshinori; Nishiyama, Takahiko; Nishiyama, Nobuhiro; Fukumoto, Kotaro; Tanimoto, Yoko; Aizawa, Yoshiyasu; Fukuda, Keiichi; Takatsuki, Seiji.

In: Journal of Cardiology, 30.06.2015.

Research output: Contribution to journalArticle

Kimura, T, Igarashi, A, Ikeda, S, Nakajima, K, Kashimura, S, Kunitomi, A, Katsumata, Y, Nishiyama, T, Nishiyama, N, Fukumoto, K, Tanimoto, Y, Aizawa, Y, Fukuda, K & Takatsuki, S 2015, 'A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS2 score in Japan', Journal of Cardiology. https://doi.org/10.1016/j.jjcc.2016.01.008
Kimura, Takehiro ; Igarashi, Ataru ; Ikeda, Shunya ; Nakajima, Kazuaki ; Kashimura, Shin ; Kunitomi, Akira ; Katsumata, Yoshinori ; Nishiyama, Takahiko ; Nishiyama, Nobuhiro ; Fukumoto, Kotaro ; Tanimoto, Yoko ; Aizawa, Yoshiyasu ; Fukuda, Keiichi ; Takatsuki, Seiji. / A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS2 score in Japan. In: Journal of Cardiology. 2015.
@article{5cc55b15dd934f819a355bbccaf18503,
title = "A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS2 score in Japan",
abstract = "Background: We aimed to clarify the cost-effectiveness of an expensive combination therapy for atrial fibrillation (AF) using both catheter ablation and dabigatran compared with warfarin at each CHADS2 score for patients in Japan. Methods: A Markov model was constructed to analyze costs and quality-adjusted life years associated with AF therapeutic options with a time horizon of 10 years. The target population was 60-year-old patients with paroxysmal AF. The indication for anticoagulation was determined according to the Japanese guideline. Anticoagulation-related data were derived from the RE-LY study and the AF recurrence rate was set at 2.7{\%} per month during the first 12 months and at 0.40{\%} per month afterwards. Stroke risk was determined according to AF recurrence, anticoagulation, and CHADS2 score. The risks for stroke recurrence and stroke death were also considered. Costs were calculated from the healthcare payer's perspective, and only direct medical costs were included. Results: Warfarin was the most preferred option for patients with a CHADS2 score of 0 from a health economics aspect. Ablation under warfarin was preferred for a CHADS2 score of 1-3, while ablation under dabigatran was preferred for a CHADS2 score ≥4. The quality of life score for AF had the largest impact on the incremental cost-effectiveness ratios in the analysis between the anticoagulation arm and the anticoagulation+ablation arm for a CHADS2 score of 2. Within the range of the Japanese willingness-to-pay threshold (¥5,000,000), the ablation+warfarin arm became the best option with its probability of 81.7{\%} for a CHADS2 score of 2; the dabigatran+ablation arm was the most preferred option with its probability of 56.1{\%} for a CHADS2 score of 4. Conclusions: Ablation under dabigatran therapy is an expensive therapeutic option, but it might benefit patients with a low quality of life and a high CHADS2 score.",
keywords = "Atrial fibrillation, Catheter ablation, Cost-utility analysis, Dabigatran, Warfarin",
author = "Takehiro Kimura and Ataru Igarashi and Shunya Ikeda and Kazuaki Nakajima and Shin Kashimura and Akira Kunitomi and Yoshinori Katsumata and Takahiko Nishiyama and Nobuhiro Nishiyama and Kotaro Fukumoto and Yoko Tanimoto and Yoshiyasu Aizawa and Keiichi Fukuda and Seiji Takatsuki",
year = "2015",
month = "6",
day = "30",
doi = "10.1016/j.jjcc.2016.01.008",
language = "English",
journal = "Journal of cardiography. Supplement",
issn = "0914-5087",
publisher = "Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)",

}

TY - JOUR

T1 - A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS2 score in Japan

AU - Kimura, Takehiro

AU - Igarashi, Ataru

AU - Ikeda, Shunya

AU - Nakajima, Kazuaki

AU - Kashimura, Shin

AU - Kunitomi, Akira

AU - Katsumata, Yoshinori

AU - Nishiyama, Takahiko

AU - Nishiyama, Nobuhiro

AU - Fukumoto, Kotaro

AU - Tanimoto, Yoko

AU - Aizawa, Yoshiyasu

AU - Fukuda, Keiichi

AU - Takatsuki, Seiji

PY - 2015/6/30

Y1 - 2015/6/30

N2 - Background: We aimed to clarify the cost-effectiveness of an expensive combination therapy for atrial fibrillation (AF) using both catheter ablation and dabigatran compared with warfarin at each CHADS2 score for patients in Japan. Methods: A Markov model was constructed to analyze costs and quality-adjusted life years associated with AF therapeutic options with a time horizon of 10 years. The target population was 60-year-old patients with paroxysmal AF. The indication for anticoagulation was determined according to the Japanese guideline. Anticoagulation-related data were derived from the RE-LY study and the AF recurrence rate was set at 2.7% per month during the first 12 months and at 0.40% per month afterwards. Stroke risk was determined according to AF recurrence, anticoagulation, and CHADS2 score. The risks for stroke recurrence and stroke death were also considered. Costs were calculated from the healthcare payer's perspective, and only direct medical costs were included. Results: Warfarin was the most preferred option for patients with a CHADS2 score of 0 from a health economics aspect. Ablation under warfarin was preferred for a CHADS2 score of 1-3, while ablation under dabigatran was preferred for a CHADS2 score ≥4. The quality of life score for AF had the largest impact on the incremental cost-effectiveness ratios in the analysis between the anticoagulation arm and the anticoagulation+ablation arm for a CHADS2 score of 2. Within the range of the Japanese willingness-to-pay threshold (¥5,000,000), the ablation+warfarin arm became the best option with its probability of 81.7% for a CHADS2 score of 2; the dabigatran+ablation arm was the most preferred option with its probability of 56.1% for a CHADS2 score of 4. Conclusions: Ablation under dabigatran therapy is an expensive therapeutic option, but it might benefit patients with a low quality of life and a high CHADS2 score.

AB - Background: We aimed to clarify the cost-effectiveness of an expensive combination therapy for atrial fibrillation (AF) using both catheter ablation and dabigatran compared with warfarin at each CHADS2 score for patients in Japan. Methods: A Markov model was constructed to analyze costs and quality-adjusted life years associated with AF therapeutic options with a time horizon of 10 years. The target population was 60-year-old patients with paroxysmal AF. The indication for anticoagulation was determined according to the Japanese guideline. Anticoagulation-related data were derived from the RE-LY study and the AF recurrence rate was set at 2.7% per month during the first 12 months and at 0.40% per month afterwards. Stroke risk was determined according to AF recurrence, anticoagulation, and CHADS2 score. The risks for stroke recurrence and stroke death were also considered. Costs were calculated from the healthcare payer's perspective, and only direct medical costs were included. Results: Warfarin was the most preferred option for patients with a CHADS2 score of 0 from a health economics aspect. Ablation under warfarin was preferred for a CHADS2 score of 1-3, while ablation under dabigatran was preferred for a CHADS2 score ≥4. The quality of life score for AF had the largest impact on the incremental cost-effectiveness ratios in the analysis between the anticoagulation arm and the anticoagulation+ablation arm for a CHADS2 score of 2. Within the range of the Japanese willingness-to-pay threshold (¥5,000,000), the ablation+warfarin arm became the best option with its probability of 81.7% for a CHADS2 score of 2; the dabigatran+ablation arm was the most preferred option with its probability of 56.1% for a CHADS2 score of 4. Conclusions: Ablation under dabigatran therapy is an expensive therapeutic option, but it might benefit patients with a low quality of life and a high CHADS2 score.

KW - Atrial fibrillation

KW - Catheter ablation

KW - Cost-utility analysis

KW - Dabigatran

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=84959449900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959449900&partnerID=8YFLogxK

U2 - 10.1016/j.jjcc.2016.01.008

DO - 10.1016/j.jjcc.2016.01.008

M3 - Article

C2 - 26947099

AN - SCOPUS:84959449900

JO - Journal of cardiography. Supplement

JF - Journal of cardiography. Supplement

SN - 0914-5087

ER -